TG Therapeutics (LTS:0VGI) EPS (Basic): $3.18 (TTM As of Mar. 2026)


LTS:0VGI TG Therapeutics Inc LTS:0VGI
82 GF Score
Price $36.65
GF Value $39.71
! 7 Warning Signs
View Full Analysis

What is TG Therapeutics EPS (Basic)?

TG Therapeutics LTS:0VGI 82 EPS (Basic) is $3.18 as of Mar. 2026. GuruFocus rates LTS:0VGI with a GF Score™ of 82/100 and a GF Value™ of $39.71. The stock has 7 warning signs investors should review.

TG Therapeutics's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was $0.14. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was $3.18.

TG Therapeutics's EPS (Diluted) for the three months ended in Mar. 2026 was $0.12. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $2.86.

TG Therapeutics's EPS without NRI for the three months ended in Mar. 2026 was $0.18. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 2.92.

During the past 12 months, TG Therapeutics's average EPS without NRIGrowth Rate was 1115.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, TG Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 86.20% per year. The lowest was -76.50% per year. And the median was 16.75% per year.

TG Therapeutics  (LTS:0VGI) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

TG Therapeutics EPS (Basic) Related Terms

TG Therapeutics EPS (Basic) Historical Data

* Premium members only.

The historical data trend for TG Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TG Therapeutics EPS (Basic) Chart

TG Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.63 -1.65 0.09 0.16 3.10

TG Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.19 2.69 0.16 0.14
LTS:0VGI
82GF Score
TG Therapeutics Inc LTS:0VGI
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TG Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

TG Therapeutics's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(447.179-0)/144.317
=3.10

TG Therapeutics's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(19.777-0)/144.439
=0.14

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $3.18 mean?
TG Therapeutics (LTS:0VGI) has a EPS (Basic) of $3.18 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on TG Therapeutics and its competitors.
Is TG Therapeutics' EPS (Basic) too high?
TG Therapeutics' current EPS (Basic) is $3.18. Overall, TG Therapeutics has a GF Score™ of 82/100, reflecting its overall financial health beyond just this single metric.
How does TG Therapeutics' EPS (Basic) compare to SRRK and COGT?
TG Therapeutics' EPS (Basic) of $3.18 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on TG Therapeutics and its competitors. TG Therapeutics's current EPS (Basic) is $3.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TG Therapeutics stock overvalued right now?
TG Therapeutics (LTS:0VGI) has a current EPS (Basic) of $3.18. The stock's GF Value™ is $39.71, compared to a current price of $36.65 — trading 7.7% below its estimated fair value. The current EPS (Basic) is $3.18. TG Therapeutics' overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For TG Therapeutics (LTS:0VGI), the current EPS (Basic) is $3.18 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TG Therapeutics (LTS:0VGI) Overvalued in 2026?

Based on GuruFocus' analysis, TG Therapeutics stock appears to be undervalued. The current stock price of $36.65 is trading 7.7% below its estimated GF Value™ of $39.71.

Key valuation signals for LTS:0VGI:

  • EPS (Basic): $3.18
  • GF Value™: $39.71 vs. price of $36.65 (7.7% below fair value)
  • GF Score™: 82/100 with 7 warning signs

No single metric tells the full story. See the LTS:0VGI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TG Therapeutics Business Description

Address 3020 Carrington Mill Boulevard, Suite 475, Morrisville, NC, USA, 27560
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
82GF Score

Get the complete analysis for LTS:0VGI

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$36.65
Price
$39.71
GF Value